Country: Canada
Language: English
Source: Health Canada
LORAZEPAM
SANDOZ CANADA INCORPORATED
N05BA06
LORAZEPAM
4MG
SOLUTION
LORAZEPAM 4MG
INTRAMUSCULAR
1 ML
Targeted (CDSA IV)
BENZODIAZEPINES
Active ingredient group (AIG) number: 0110731004; AHFS:
APPROVED
2005-08-12
LORAZEPAM INJECTION USP _(lorazepam)_ _ _ Page 1 of 35 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION C/T LORAZEPAM INJECTION USP Lorazepam Injection, 4 mg/mL, intravenous, intramuscular USP Anxiolytic – Sedative Sandoz Canada Inc. 110 Rue de Lauzon Boucherville, QC, Canada J4B 1E6 Date of Initial Authorization: JUN 6, 2001 Date of Revision: JUL 18, 2023 Submission Control No.: 272297 LORAZEPAM INJECTION USP _(lorazepam)_ _ _ Page 2 of 35 RECENT MAJOR LABEL CHANGES 1 INDICATIONS, 1.2 Geriatrics 12/2021 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 12/2021 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations 07/2023 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dosage and Dosage Adjustment 07/2023 7 WARNINGS AND PRECAUTIONS 12/2021 7 WARNINGS AND PRECAUTIONS, Dependence/Tolerance 07/2023 7 WARNINGS AND PRECAUTIONS, 7.1.4 Geriatrics 12/2021 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics ................................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................. 5 4 DOSAGE AND ADMINISTRATION .................................................................... Read the complete document